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-Catenin controls both cadherin-mediated cell adhe-
sion and activation of Wnt target genes. We demonstrate
here that the -catenin-binding protein BCL9-2, a homo-
log of the human proto-oncogene product BCL9, induces
epithelial–mesenchymal transitions of nontransformed
cells and increases -catenin-dependent transcription.
RNA interference of BCL9-2 in carcinoma cells induces
an epithelial phenotype and translocates -catenin from
the nucleus to the cell membrane. The switch between
-catenin’s adhesive and transcriptional functions is
modulated by phosphorylation of Tyr 142 of -catenin,
which favors BCL9-2 binding and precludes interaction
with -catenin. During zebrafish embryogenesis,
BCL9-2 acts in the Wnt8-signaling pathway and regu-
lates mesoderm patterning.
Received May 27, 2004; revised version accepted July 20,
2004.
Wnt/-catenin signals act in concert with other signal-
ing systems to control patterning in early, and organo-
genesis in late stages of development (De Robertis et al.
2000; Huelsken and Birchmeier 2001; Moon et al. 2002).
In the adult, deregulated Wnt/-catenin signaling can
cause tumors (Bienz and Clevers 2000). In the presence of
Wnt signals, cytoplasmically located -catenin is stabi-
lized and interacts with transcription factors of the Lef/
Tcf family to control nuclear transcription (Behrens et al.
1996; Korinek et al. 1997; Eastman and Grosschedl
1999). -Catenin also functions in cell adhesion at the
plasma membrane, where it connects cadherins to
-catenin and the cytoskeleton (Takeichi 1995). The mo-
lecular mechanism of the switch between the adhesive
and transcriptional functions of -catenin was unknown.
In B-cell lymphomas, chromosomal translocations can
activate proto-oncogenes (Rowley 2001). The t(1;14)(q21;q32)
translocation uncovered the BCL9 gene, and caused
BCL9 overexpression in the tumors (Willis et al. 1998).
Recently legless, the Drosophila ortholog of BCL9, was
found to act as a segment polarity gene and to function in
the Wnt/-catenin pathway in cooperation with pygopus
(Kramps et al. 2002; Thompson et al. 2002). The role of
BCL9 proteins in vertebrate development and tumor pro-
gression had not been determined.
Results and Discussion
Vertebrate BCL9-2 proteins show an overall amino acid
sequence identity of 60%, and 35% identity to the hu-
man proto-oncogene product BCL9 (Fig. 1A; see Gen-
Bank AY296057 to AY296061; Willis et al. 1998). Up to
90% sequence identity was found in seven short clusters
of 20–30 amino acids, which are also conserved in legless
from Drosophila (this study; Kramps et al. 2002): the
-catenin-binding domain (-catBD), the pygopus (PyBD)-
binding domain, a domain that contains a classical
nuclear localization signal (NLS, KRRK motif), three C-
terminal homology domains (C-HD1 to C-HD3), and
a novel N-terminal homology domain (N-HD) that
contains a lysine-rich potential sumoylation motif
(K*K*KXE/D; in amino acid residues 108–137; Melchior
2000) and a sequence similar to classical nuclear local-
ization signals (PRSKRRC; in amino acids 138–173;
Hicks and Raikhel 1995).
BCL9-2 in nontransformed cells induces
epithelial–mesenchymal transition, nuclear
translocation of -catenin, and increases cell migration
We expressed BCL9-2 in epithelial MDCK cells and es-
tablished cell clones that had stably incorporated the ex-
pression vector. Control cells formed round compact
colonies at subconfluency, and exhibited the typical
cobblestone morphology of epithelial cells (Fig. 1B, top
left). In contrast, BCL9-2 expressing colonies were flat-
tened and irregularly shaped, and contained scattered
cells (Fig. 1B, bottom left). Moreover, BCL9-2 expressing
colonies were completely scattered in the presence of
suboptimal dosages of Hepatocyte Growth Factor (HGF;
Fig. 1B, bottom, middle, and right), which activates the
receptor tyrosine kinase Met (Birchmeier et al. 2003).
Control clones were not scattered at these low concen-
trations of HGF (Fig. 1B, top, middle, and right). BCL9-
2-expressing cells also exhibited a threefold increased
cell migration, as observed in Transwell cultures (data
not shown). These results suggest that BCL9-2 induces
epithelial–mesenchymal transitions, and that tyrosine
phosphorylation by Met collaborates with BCL9-2 ac-
tion.
Epithelial–mesenchymal transitions correlated with
complex formation of BCL9-2 and -catenin in the
nucleus of the scattered cells; BCL9-2 was located in the
nucleus (the nucleoli were excluded) and translocated
-catenin to the nuclear compartment (Fig. 1C, bottom),
whereas -catenin located at the plasma membrane, but
not in the nucleus in control cells (Fig. 1C, top). A frag-
ment of BCL9-2 that contains only the N-terminal do-
main (amino acids 1–175) also located to the nucleus
(Fig. 1D, left). In contrast, BCL9-2 with a deletion of the
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nuclear localization signal of the N-terminal domain
( amino acids 138–173) was located in the cytoplasm
(Fig. 1D, middle). Mutations of the putative sumoylation
motif in the N-terminal domain of BCL9-2 (e.g., the
K110R mutation) favored accumulation in nuclear bod-
ies (Fig. 1D, right). The BCL9/legless homologs, which
lack the nuclear localization signal in the N-terminal
domain, did not localize to the nucleus (data not shown;
see also Townsley et al. 2004).
Tyrosine phosphorylation of -catenin also contrib-
uted to nuclear translocation, a deletion fragment of
BCL9-2 that contained only the -catenin-binding do-
main (amino acids 387–530) located to the cytoplasm
(Fig. 1E, top). Upon HGF treatment, -catenin was par-
tially released from the plasma membrane, translocated
to the nucleus, where it colocalized with the BCL9-2
fragment (Fig. 1E, bottom).
RNA interference of BCL9-2 in transformed cells
induces reversion to the epithelial phenotype and
translocates -catenin from the nucleus to the
plasma membrane
We used colon cancer cell lines that exhibit activated
Wnt/-catenin signaling by mutation of the tumor sup-
pressor gene APC (Behrens et al. 1998). SW480 cells are
fibroblast-like and show high levels of nuclear -catenin
(Fig. 2B, top), and they express high levels of BCL9-2 (Fig.
2A). Transfection with specific siRNAs against BCL9-2
Figure 1. BCL9-2 induces epithelial–mesenchymal transition and
nuclear translocation of -catenin in MDCK cells. (A) Domain
structure of the vertebrate BCL9-2 protein. The seven conserved
domains are highlighted; positions of amino acids are indicated. (B)
Morphology of BCL9-2-transfected MDCK cells and controls. HGF
treatment was for 18 h. (C) Immunofluorescence microscopy of
MDCK cells for endogenous -catenin (red), transfected BCL9-2
(green), and merged fluorescence (yellow). Arrows mark -catenin
collocation with BCL9-2 (see also inset). (D) Cellular localization of
deletions and point mutants of BCL9-2. (E) Localization of the iso-
lated -catenin-binding fragment of BCL9-2 (amino acids 387–530)
in MDCK cells. Treatment with 2 U mL−1 HGF was for 6 h. The
used BCL9-2 constructs are schematically indicated in the figures.
Figure 2. RNA interference of BCL9-2 in transformed cells reverts
cells to the epithelial phenotype, translocates -catenin from the
nucleus to the plasma membrane, and reverts transformed proper-
ties. (A, left) Northern blot of SW480 cells that were transfected
with BCL9-2 siRNAs or controls for 24 and 48 h. The used probes are
indicated on the left. (Right) Western blot of nuclear extracts of
HEK293 cells that were stably transfected with BCL9-2 or control
vector, and treated for 96 h with BCL9-2 siRNAs. (B) Morphology
and immunofluorescence of endogenous -catenin of SW480 cells
that were transfected with BCL9-2 siRNAs or controls for 72 h. (C,
left) Cell migration of SW480 cells that were treated with BCL9-2
siRNAs or controls for 72 h. The number of migrating cells (from
three independent transfections) is expressed as percent of control
cells. (Right) Colony formation of DLD-1 cells that were treated
with BCL9-2 siRNAs or controls for 72 h. Colonies in soft agar (from
three independent transfections) were counted after 10 d and ex-
pressed as percent of controls.
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reduced endogenous BCL9-2 (but not BCL9) RNA lev-
els almost completely within 24 h, and abolished pro-
tein expression of transfected BCL9-2 in HEK293 cells
(Fig. 2A). Remarkably, the morphology of the BCL9-2
siRNAs-treated SW480 cells became epithelial-like, and
-catenin was translocated from the nucleus to the cell
membrane (Fig. 2B, bottom). Moreover, cell migration of
the treated SW480 cells was drastically reduced (Fig. 2C,
left). BCL9-2 siRNA’s treatment of DLD-1 colon cancer
cells also induced loss of nuclear -catenin, and the cells
showed reduced colony formation in soft agar (Fig. 2C,
right; data not shown).
Tyrosine phosphorylation of -catenin controls
complex formation with BCL9-2
We initially identified BCL9-2 as an interaction partner
of tyrosine-phosphorylated -catenin in a yeast two-hy-
brid screen. BCL9-2 interacted efficiently with -catenin
in yeast when the armadillo domains were fused to ki-
nase-active, but not to kinase-defective Met (Fig. 3A; see
also Fujita et al. 2002 for construction of yeast baits).
Armadillo repeats 1 and 2 of -catenin are required to
bind BCL9-2, which contain only one tyrosine residue at
position 142. Mutation of Y142 to alanine indeed abro-
gated BCL9-2 binding, whereas mutation to
glutamic acid (Y142E), which can mimic tyro-
sine phosphorylation, increased binding effi-
ciency (Fig. 3A).
The presence of a nonphosphorylated Tyr
142 in -catenin is required for -catenin bind-
ing (Aberle et al. 1996; Pokutta and Weis
2000). The mutations Y142A and Y142E both
abrogated binding to -catenin (Fig. 3B). Inter-
action of BCL9-2 with tyrosine-phosphory-
lated -catenin was confirmed by coimmuno-
precipitation from tissue culture cells. HGF
treatment of cells induced tyrosine phosphory-
lation of -catenin and promoted interaction
with BCL9-2 (Fig. 3C), as did the Y142E muta-
tion of -catenin in GST pull-down experi-
ments (Fig. 3D). In contrast, a strongly reduced
binding between -catenin and -catenin was
observed when the Y142A and Y142E muta-
tions were present in -catenin.
BCL9-2 promotes -catenin’s transcriptional
activity that is enhanced by
tyrosine phosphorylation
We used HEK293 cells, which contain low
levels of endogenous BCL9-2 and -catenin
(data not shown), for testing the transcrip-
tional activity of BCL9-2. Full-size BCL9-2 en-
hanced -catenin-dependent transcription
threefold (Fig. 4A). BCL9-2 had no effect in the
absence of -catenin. Moreover, mutation of
the conserved lysines in the potential sum-
oylation motif of the N-terminal domain of
BCL9-2 (K108R, K110R, or K112R) activated -
catenin-dependent transcription up to nine-
fold (Fig. 4A; data not shown). Remarkably, ex-
pression of the BCL9-2 fragment that contains
the -catenin-binding domain only (amino ac-
ids 387–530) and does not affect binding of
-catenin to Lef/Tcfs abolished -catenin-dependent
transcription (Fig. 4A; data not shown). Deletion of the
nuclear localization signal in the N-terminal domain of
BCL9-2 ( amino acids 138–173) abolished transcrip-
tional activation. Internal deletion of the previously
identified pygopus-binding domain of BCL9 proteins
showed that this domain is not required in BCL9-2 to
potentiate -catenin’s transcriptional activity (data not
shown). BCL9/legless stimulated transcription to a simi-
lar degree, but this activation was dependent on the py-
gopus-binding domain (data not shown; see also Towns-
ley et al. 2004). BCL9-2 expression increased -catenin-
dependent transcription also in other assays, as assessed
for the expression levels of the Wnt target gene conduc-
tin (data not shown; Lustig et al. 2002). BCL9-2 siRNA
treatment of SW480 and DLD-1 cells significantly re-
duced transcriptional activity of -catenin (Fig. 4B).The
coactivator function of BCL9-2 depended on Y142 of
-catenin; in the presence of -catenin that contains a
Y142A mutation, BCL9-2 had a reduced effect on tran-
scription (Fig. 4C, top). -Catenin blocked -catenin’s
transcriptional activity (Fig. 4C; Giannini et al. 2000).
This inhibition was overcome by cotransfected BCL9-2,
but only in the presence of wild-type and not of Y142A
mutant -catenin (Fig. 4C, bottom). We also forced tyro-
Figure 3. Phosphorylation of Tyr 142 of -catenin mediates complex formation
with BCL9-2 and reduces -catenin binding. (A) Interaction of tpr–Met–-catenin
fusion proteins, of -catenin repeats 1–4, and Y142 mutations thereof with BCL9-2
(amino acids 387–530), as determined by yeast two-hybrid assays. Arm repeats of
-catenin are depicted by numbers. (KA) kinase-active; (KD) kinase-defective fusion
proteins. (B) Interaction of -catenin and Y142 mutations thereof with -catenin.
Note that constructs without tpr–met were in the prey, BCL9-2 in the bait vectors.
Interactions (+ or −) were quantified by growth of yeast on selective medium and by
-galactosidase activity in solution. (C) Interaction of BCL9-2 and tyrosine-phos-
phorylated -catenin in COS-7 cells in response to HGF treatment (5 U mL−1 for 18
h), as determined by coimmunoprecipitation. BCL9-2 (amino acids 387–530) was
cotransfected with full-length -catenin. (D) Interaction of BCL9-2 and -catenin
with wild-type and Y142 mutant -catenin, as determined by GST--catenin pull-
down experiments. BCL9-2 (amino acids 387–530) and full size -catenin were pre-
pared from transfected COS-7 cells.
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sine phosphorylation of -catenin by HGF treatment of
cells and by cotransfection of the receptor tyrosine ki-
nase trk-Met (Fig. 4D; Schaeper et al. 2000). BCL9-2 co-
factor function was increased, but only in the case of
wild-type, and not Y142A mutant -catenin (Fig. 4D).
BCL9-2 controls mesoderm patterning in
zebrafish embryogenesis
In zebrafish embryos, BCL9-2 and BCL9 mRNAs are con-
tributed maternally and are highly expressed during gas-
trulation (data not shown). Injection of antisense BCL9-2
morpholinos (MOs) into zebrafish embryos resulted in
severe defects of trunk and tail developmental (Fig. 5A).
BCL9-2 MOs directed against the start codon were
highly effective at minimal dosages (0.03 pmole/em-
bryo). The mutant phenotype was observed in 80% of the
cases (n = 450). In contrast, different MOs against the
homolog BCL9/legless had no effect (n = 375; data not
shown). Moreover, coinjection of BCL9-2 and BCL9 MOs
did not alterate the developmental defects induced by
BCL9-2 MOs alone (n = 150; data not shown).The loss-
of-function of BCL9-2 suggested a deficit in Wnt8 signal-
ing (Erter et al. 2001; Lekven et al. 2001). At 70% epiboly
of wild-type embryos, floating head was expressed in the
dorsal axial mesoderm, and tbx6 in the ventro–lateral
mesoderm. After injections of BCL9-2 MOs, the expres-
sion of floating head was broadened, and tbx6 expression
was lost (Fig. 5B,C; data not shown). Moreover, injection
of low concentrations of MOs against BCL9-2 and Wnt8
synergized to suppress tbx6 expression in the ventro–
lateral mesoderm (data not shown). No change of expres-
sion of pax2.1 or otx2 in the neuroectoderm was ob-
served (data not shown). Loss of tbx6 expression induced
by BCL9-2 MOs was completely rescued by mouse
BCL9-2 mRNA, indicating that the MOs specifically tar-
get zebrafish BCL9-2 (Fig. 5D). Injection of mouse
BCL9-2 mRNA alone expanded tbx6 expression (Fig. 5E).
Injection of BCL9-2 mRNA that encodes a fragment
lacking the N-terminal domain did not expand tbx6 ex-
pression, nor did such injection rescue the phenotypes of
Figure 4. BCL9-2 is an essential nuclear coactivator of -catenin
signaling. (A) Transcriptional activation of -catenin and BCL9-2 in
HEK293 cells. Deletions and mutants of BCL9-2 are shown sche-
matically on the left. A total of 0.5 µg of S33A -catenin and 1.0–3.0
µg of BCL9-2 were cotransfected with the TOP (gray bars) or the
control FOP reporter (open bars). (B) Transcriptional activation of
-catenin in SW480 and DLD-1 colon carcinoma cells that were
treated with BCL9-2 siRNAs or controls for 48 and 72 h. Transfec-
tion with the reporters was for another 24 h. (C) Transcriptional
activation in HEK293 cells of wild-type or Y142A mutant -catenin,
and effects of cotransfected BCL9-2 and -catenin; 0.5 µg -catenin,
1.0 µg -catenin, and 0.25–1.0 µg BCL9-2 were transfected. (D) Tran-
scriptional activation of -catenin and the Y142A mutant in re-
sponse to HGF treatment (50 U mL−1 for 18 h) or by cotransfected
trk-Met (0.15 µg); 0.25 µg -catenin and 3.0 µg BCL9-2 were trans-
fected. HEK293 cells were cultured at reduced serum concentrations
(50% DMEM and 50% OptimemI, Invitrogen).
Figure 5. BCL9-2 in zebrafish embryos acts downstream in the
Wnt8/-catenin pathway to pattern the ventro–lateral mesoderm.
(A) Malformations of trunk and tail in embryos treated with BCL9-2
ATG MOs at 26 h post-fertilization. Dependence on the amount of
injected MOs. (B–E) Effects of BCL9-2 MOs on the expression of the
ventro–lateral mesoderm marker tbx6 at 70% epiboly. BCL9-2 MOs
(0.03 pmole; C), BCL9-2 MOs in combination with mouse BCL9-2
RNA (1.5 ng; D), and mBCL9-2 RNA alone (E). Control is in B. (F–I)
Epistasis of the action of Wnt8, Diversin, and BCL9-2, as examined
by expression of tbx6. Wnt8 DNA (0.06 ng; F), Diversin MOs (0.6
pmole; H), and in combination with BCL9-2 MOs (G,I). Lateral view,
anterior up, dorsal to the right.
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BCL9-2 MOs (data not shown).We also examined the
epistasic relationship between Wnt8, Diversin (a nega-
tive regulator of -catenin signaling; Schwarz-Romond
et al. 2002) and BCL9-2 in zebrafish embryos. Injection of
Wnt8 DNA or stabilization of -catenin by injection of
Diversin MOs lead to an expansions of tbx6 expression
(Fig. 5F,H; an increase of tbx6 by Wnt8 in 100%, n = 45,
and by Diversin MOs in 85%, n = 52). This was com-
pletely blocked by coinjection of BCL9-2 MOs (Fig. 5G,I;
loss of tbx6 by Wnt8 plus BCL9-2 MOs in 89%, n = 39,
and by Diversin plus BCL9-2 MOs in 81%, n = 33).
Epithelial–mesenchymal transitions occur during
critical phases of embryonic development. Such transi-
tions are also observed late in the progression of carci-
nomas and provide a possible metastatic mechanism.
Several signaling systems can induce epithelial–mesen-
chymal transitions, such as Wnt/-catenin, TGF/
BMPs, or tyrosine kinases (Hay 1995; Thiery 2002; Birch-
meier et al. 2003). Epithelial–mesenchymal transitions
are initiated by a breakdown of the E-cadherin/-
catenin/-catenin complex at the plasma membrane and
a dissociation of this adhesive complex from the cyto-
skeleton, which can be induced by tyrosine phosphory-
lation of -catenin (Behrens et al. 1993; Fujita et al. 2002;
Piedra et al. 2003). We demonstrate here that BCL9-2
forms a complex with -catenin that is phosphorylated
at Tyr 142, which precludes interaction with -catenin.
Phosphorylation of Tyr 142 of -catenin and interaction
with BCL9-2 allows location of the complex in the
nucleus and increases transcription of Wnt/-catenin
target genes. Thus, BCL9-2 appears to contribute to on-
cogenicity by two mechanisms: (1) interfering with cad-
herins, which act as tumor suppressor genes (Birchmeier
and Behrens 1994; Perl et al. 1998), and (2) by increased
signaling of family members of the Wnt pathway, which
contains many oncogenes and tumor suppressor genes
(Bienz and Clevers 2000; Polakis 2000).
During vertebrate embryogenesis, Wnt/-catenin sig-
nals control formation of the dorso–anterior axis and pat-
terning of the mesoderm at early, and organ specification
at later stages of development (De Robertis et al. 2000;
Huelsken and Birchmeier 2001; Moon et al. 2002). In
zebrafish embryos, Wnt8/-catenin signaling is required
to pattern ventro–lateral mesoderm and to posteriorize
neural ectoderm (Erter et al. 2001; Lekven et al. 2001).
We show here that BCL9-2, but not the homolog BCL9/
legless, is essential for mesoderm patterning in early ze-
brafish embryogenesis, and that BCL9-2 acts down-
stream of Wnt8/-catenin. However, BCL9-2 does not
appear to be required for other early functions of the
canonical Wnt pathway, such as formation of the dorsal
organizer or posteriorization of anterior neuroectoderm
(Kelly et al. 2000; Lekven et al. 2001). Our data therefore
suggest that BCL9-2 acts as a specific modulator of ca-
nonical Wnt signaling at particular developmental
stages, rather than as a general component of Wnt sig-
naling.
Materials and methods
cDNAs of BCL9s were obtained by RT–PCR of total RNA from human
HEK293 cells, mouse liver tissue, or zebrafish tailbud stage embryos. The
5 UTR of zebrafish BCL9-2 was produced by 5RACE (Clontech). Dele-
tion constructs of mouse BCL9-2 and human -catenin were generated by
restriction enzyme digests and PCR amplification. The point mutations
K108R, K110R, and K112R of BCL9-2, and of Y142 of -catenin were
generated by overlapping PCR mutagenesis.
Analysis of BCL9-2 function in cultured cells
Yeast two-hybrid screens were performed as described (Behrens et al.
1996; Schaeper et al. 2000). Tagged cDNA constructs were transfected in
the indicated cell lines using Lipofectamine 2000 (Invitrogen), and pro-
tein expression was analyzed using anti-flag (Sigma), anti-HA (Roche),
rabbit anti--catenin, and anti-PY20 antibodies as described (Behrens et
al. 1996; Fujita et al. 2002). Immunofluorescence was detected with anti-
flag and anti--catenin antibodies, followed by Cy3- and Alexa Fluor
488-conjugated secondary antibodies (Jackson Immunoresearch and Mo-
lecular Probes). Transcriptional activity of -catenin was measured as
described (Korinek et al. 1997; Schwarz-Romond et al. 2002). Equal ex-
pression of the transfected BCL9-2 constructs was monitored by Western
blotting. siRNAs against human BCL9-2 were obtained from Dharma-
con, and 100 nM of four pooled siRNAs were transfected using Lipofect-
amine 2000. The sequences were 5-GAACAGCAGTGGCGTGATG-3,
5-GCTGATGCCTTCACAGTTT-3, 5-GACCTCACCATCAGTATTA-3,
and 5-CAGGCAACCTCAACATGAA-3. Cell migration was deter-
mined in Transwell chambers (12-mm diameter, 12-µm pore size; Cor-
ning) with 5 × 104 cells, using a CellTiter-Glo assay (Promega). Colony
formation was determined in a clonogenic assay with 1 × 103 cells, as
described (Brembeck et al. 1998).
Analysis of BCL9-2 function in zebrafish embryos
Embryos from the AB-Strain were injected into the yolk at the one-to-
four-cell stage, and in situ hybridizations were performed as described
(Hammerschmidt et al. 1996; Nasevicius and Ekker 2000). Antisense
MOs were obtained from Gene Tools. The BCL9-2 ATG MO was TG
CATTTGATTGGCTGGTGATGGAG. Other MO sequences can be ob-
tained upon request (brembeck@mdc-berlin.de). Sequences of Wnt8 1 + 2
and Diversin MOs were as published (Lekven et al. 2001; Schwarz-Ro-
mond et al. 2002).
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